Jefferies Global Healthcare Conference in London - LIQUIDIA CORP
Financial Performance:
- Achieved over 30% market share in the entrenched PAH inhaled prostacyclin market by September 2026, surpassing the market leader's 20-year head start.
- October 2026 showed a 75% daily referral rate relative to Q3 2026, described as the most disruptive month of the launch.
- Projected to achieve over 50% operating margins by 2027, with SG&A expenses as a percentage of sales decreasing quarterly.
- Entered Q4 2026 with approximately $400 million in cash reserves.
- Committed to net settlement payments totaling approximately $380 million to United Therapeutics, concluding with the final payment in April 2027; no ongoing royalties or future payments are required post-settlement.
Guidance and Future Outlook:
- Confirmed a "show me" growth story strategy, focusing on execution through 2027 and beyond post-settlement.
- Plans to initiate 10 clinical trials by late 2027, including three registrational studies: L606 in PH-COPD, L606 in PH-ILD, and a pivotal Phase 3 study for Systemic Sclerosis with Raynaud's Phenomenon.
- Aims to complete enrollment for the L606 Amplify PAH study by 2028, with data expected in 2029 to support NDA filing.
- Expecting continued sequential growth in Eutrepia revenue through Q4 2027 and beyond, driven by expansion into new patient pools and higher dosing flexibility.
- Long-term goal is to establish L606 as the dominant treatment force for PAH, while Eutrepia focuses on niche indications like systemic sclerosis.
Business Segments and Product Lines:
- Eutrepia: Positioned as the only inhaled prostacyclin with a 3-5 times daily dosing regimen and high titration flexibility; currently serving PAH and PH-ILD patients who are not required to switch due to the settlement.
- L606: A next-generation nebulized treprostinil product in the 505(b)(1) pathway, featuring twice-daily dosing for sustained systemic exposure; currently in global Phase 3 for PH-ILD (Respire) and preparing Phase 3 for PAH (Amplify).
- REWARM Study: Phase 2 dose-finding study initiated for systemic sclerosis with Raynaud's Phenomenon; received Fast Track designation with completion expected Q1 2027.
- Clinical Pipeline: Initiating Phase 4 open-label studies on oral and parenteral transitions for Eutrepia; planning a registry study (EZPH) in 2027 to capture real-world evidence on dosing flexibility.
- Future Indications: Prioritizing PH-COPD for L606 due to the large patient population (300,000+) and lack of approved therapies; evaluating IPF and PPF based on potential for higher dosing efficacy.
Market and Competitive Landscape:
- Operating in a $4 billion prostacyclin market for PAH; management believes access to the vast majority of this market is achievable with Eutrepia.
- Differentiation strategy focuses on dosing frequency (3-5x/day vs. competitors) and the ability to titrate to higher doses, addressing tolerability issues associated with oral prostacyclins.
- Settlement with United Therapeutics has removed legal overhang, allowing focus on commercial execution and market share gains against competitors.
- Eutrepia is the best-in-class DPI (dry powder inhaler) for inhaled prostacyclins, with L606 expected to become the best-in-class nebulized option.
Risks and Challenges:
- Reauthorization Risk: Management asserts minimal risk to existing PHILD patients in 2027, stating payers focus on patient benefit rather than switching, though annual reauthorization processes remain a monitoring point.
- Clinical Execution: Success of Phase 2 REWARM study depends on identifying a viable dose for Raynaud's that balances vasodilation with tolerability.
- Regulatory Uncertainty: L606 requires a second PAH-specific pivotal trial due to the loss of the 505(b)(2) pathway, adding complexity and timeline requirements compared to Eutrepia's approval.
- IP Landscape: While the 327 patent is specific to Tyvaso's breath-actuated delivery, management maintains clear freedom to operate for L606 due to its distinct nebulized dosing mechanism, though remains prepared for potential litigation.
Management Commentary and Tone:
- Tone is highly confident and execution-focused, describing the post-settlement environment as "extremely lucky" to service patients and build value.
- Management emphasized that the legal overhang is gone, shifting the narrative entirely to clinical milestones and commercial growth.
- CEO Roger (absent due to travel) and COO/CEO Mike Caseta expressed strong belief in the product profiles and the company's ability to outperform the market leader.
- Confidence in the 50% operating margin target and the ability to transition existing patients to Eutrepia from oral therapies.
Analyst Questions and Answers:
- Q: What are the key milestones for 2027-2029? A: Growth of Eutrepia, initiation of 10 clinical trials (including 3 registrational), and progress of L606 to NDA filing by 2029.
- Q: Which patient population (oral, inhaled, parenteral) offers the best switching opportunity? A: The entire $4B prostacyclin market; Eutrepia is positioned to capture oral and parenteral users via Phase 4 transition studies.
- Q: How will Eutrepia and L606 be segmented? A: L606 targeted primarily for new PAH patients due to twice-dosing convenience; Eutrepia retained for existing patients and specific indications like Raynaud's, with potential case-by-case transitions.
- Q: What are the capital allocation priorities post-2027? A: Generation of significant free cash flow; reinvestment into the full clinical pipeline and evaluation of external M&A opportunities.
- Q: Is there a risk of formulary changes for PHILD patients? A: No immediate risk observed; management expects payers to focus on clinical benefit during reauthorization.
Other Key Points:
- The settlement with United Therapeutics, signed in mid-October 2025 (transcript notes October 2026 as the disruption month, likely implying 2025 settlement effective through 2026 launch timeline), provides certainty for existing patients.
- L606 device technology uses a nebulizer that loads the entire dose, contrasting with breath-actuated competitors, which mitigates the 327 patent risk.
- Management highlighted the importance of real-world evidence and Phase 4 studies to support marketing claims regarding dose flexibility and transition safety.
- The company is preparing for a dual-product strategy (Eutrepia and L606) to offer patients unprecedented choice in inhaled prostacyclin therapy.
- Company
- LIQUIDIA CORP
- Keywords
- LIQUIDIA CORP